中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 41 Issue 3
Mar.  2025
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(3): 594-600

Components of tumor stroma-immune microenvironment and their interactions in intrahepatic cholangiocarcinoma

DOI: 10.12449/JCH250331
  • 1.

    Department of Pathology，Peking University Third Hospital/Department of Pathology，Peking University Health Science Center，Beijing 100191，China

  • 2.

    National Cancer Center/National Clinical Research Center for Cancer/Department of Pathology，Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing 100021，China

More Information
  • Corresponding author: GUO Limei， guolimei@bjmu.edu.cn （ORCID： 0000-0003-0430-2914）
  • Received Date: 2024-06-25
  • Accepted Date: 2024-08-15
  • Published Date: 2025-03-25
    Abstract
  • Intrahepatic cholangiocarcinoma （ICC） is a highly malignant liver tumor， and due to the absence of symptoms in its early stage and the lack of effective treatment measures， patients tend to have an extremely low 5-year survival rate. The tumor stroma-immune microenvironment （TSIME） is a complex ecosystem that changes dynamically during tumorigenesis and evolution and consists of a variety of cellular and non-cellular components， and it plays an important role in the development， proliferation， invasion， and progression of ICC and determines the heterogeneity and malignancy of ICC to a certain degree. This article reviews the cellular components （such as T cells， B cells， natural killer cells， dendritic cells， neutrophils， macrophages， myeloid-derived suppressor cells） and non-cellular components （such as chemokines and cytokines） within the ICC TSIME， as well as the complex mechanisms of interaction between these components， and it also reviews the spatial interactions between immune cells and tumor cells， in order to provide potential research directions for ICC immunotherapy and new ideas for the effective and precise treatment of ICC in the future.

     

    • FullText(HTML)
    • References(49)
  • [1]
    BRINDLEY PJ, BACHINI M, ILYAS SI, et al. Cholangiocarcinoma[J]. Nat Rev Dis Primers, 2021, 7( 1): 65. DOI: 10.1038/s41572-021-00300-2.
    [2]
    RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77( 6): 1598- 1606. DOI: 10.1016/j.jhep.2022.08.021.
    [3]
    Expert Committee of Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma( 2022 version). Expert consensus on pathological diagnosis of intrahepatic cholangiocarcinoma(2022 version)[J]. Chin J Pathol, 2022, 51( 9): 819- 827. DOI: 10.3760/cma.j.cn112151-20220517-00423.

    《肝内胆管癌病理诊断专家共识(2022版)》编写专家委员会. 肝内胆管癌病理诊断专家共识(2022版)[J]. 中华病理学杂志, 2022, 51( 9): 819- 827. DOI: 10.3760/cma.j.cn112151-20220517-00423.
    [4]
    WANG GY, HE CH. Progress in liver transplantation for intrahepatic cholangiocarcinoma[J]. Organ Transplantation, 2023, 14( 6): 789- 796. DOI: 10.3969/j.issn.1674-7445.2023144.

    汪国营, 何才华. 肝移植治疗肝内胆管癌的研究进展[J]. 器官移植, 2023, 14( 6): 789- 796. DOI: 10.3969/j.issn.1674-7445.2023144.
    [5]
    MORIS D, PALTA M, KIM C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians[J]. CA Cancer J Clin, 2023, 73( 2): 198- 222. DOI: 10.3322/caac.21759.
    [6]
    KOSHIOL J, YU BB, KABADI SM, et al. Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015[J]. BMC Cancer, 2022, 22( 1): 1178. DOI: 10.1186/s12885-022-10286-z.
    [7]
    JIN MZ, JIN WL. The updated landscape of tumor microenvironment and drug repurposing[J]. Signal Transduct Target Ther, 2020, 5( 1): 166. DOI: 10.1038/s41392-020-00280-x.
    [8]
    FABRIS L, PERUGORRIA MJ, MERTENS J, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma[J]. Liver Int, 2019, 39( Suppl 1): 63- 78. DOI: 10.1111/liv.14098.
    [9]
    GENTILINI A, PASTORE M, MARRA F, et al. The role of stroma in cholangiocarcinoma: The intriguing interplay between fibroblastic component, immune cell subsets and tumor epithelium[J]. Int J Mol Sci, 2018, 19( 10): 2885. DOI: 10.3390/ijms19102885.
    [10]
    LOEUILLARD E, CONBOY CB, GORES GJ, et al. Immunobiology of cholangiocarcinoma[J]. JHEP Rep, 2019, 1( 4): 297- 311. DOI: 10.1016/j.jhepr.2019.06.003.
    [11]
    LIN J, DAI YT, SANG C, et al. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities[J]. J Immunother Cancer, 2022, 10( 7): e004892. DOI: 10.1136/jitc-2022-004892.
    [12]
    RUFFOLO LI, JACKSON KM, KUHLERS PC, et al. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity[J]. Gut, 2022, 71( 7): 1386- 1398. DOI: 10.1136/gutjnl-2021-324109.
    [13]
    LIU D, HEIJ LR, CZIGANY Z, et al. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma[J]. J Exp Clin Cancer Res, 2022, 41( 1): 127. DOI: 10.1186/s13046-022-02340-2.
    [14]
    XIA T, LI KY, NIU N, et al. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses[J]. J Hematol Oncol, 2022, 15( 1): 37. DOI: 10.1186/s13045-022-01253-z.
    [15]
    FABRIS L, SATO K, ALPINI G, et al. The tumor microenvironment in cholangiocarcinoma progression[J]. Hepatology, 2021, 73( Suppl 1): 75- 85. DOI: 10.1002/hep.31410.
    [16]
    CHEN Z, YU MC, YAN JL, et al. PNOC expressed by B cells in cholangiocarcinoma was survival related and LAIR2 could be a T cell exhaustion biomarker in tumor microenvironment: Characterization of immune microenvironment combining single-cell and bulk sequencing technology[J]. Front Immunol, 2021, 12: 647209. DOI: 10.3389/fimmu.2021.647209.
    [17]
    THEPMALEE C, PANYA A, JUNKING M, et al. Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells[J]. Hum Vaccin Immunother, 2018, 14( 6): 1423- 1431. DOI: 10.1080/21645515.2018.1431598.
    [18]
    SAUTÈS-FRIDMAN C, PETITPREZ F, CALDERARO J, et al. Tertiary lymphoid structures in the era of cancer immunotherapy[J]. Nat Rev Cancer, 2019, 19( 6): 307- 325. DOI: 10.1038/s41568-019-0144-6.
    [19]
    DOI N, INO Y, FUSE M, et al. Correlation of vein-rich tumor microenvironment of intrahepatic cholangiocarcinoma with tertiary lymphoid structures and patient outcome[J]. Mod Pathol, 2024, 37( 2): 100401. DOI: 10.1016/j.modpat.2023.100401.
    [20]
    DING GY, MA JQ, YUN JP, et al. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma[J]. J Hepatol, 2022, 76( 3): 608- 618. DOI: 10.1016/j.jhep.2021.10.030.
    [21]
    SHI HN, LI ZS, ZHU MC. Circulating immune cells predict prognosis and clinical response to chemotherapy in cholangiocarcinoma[J]. Curr Med Chem, 2024. DOI: 10.2174/0109298673296618240424095548.[ Online ahead of print]
    [22]
    OLIVIERO B, VARCHETTA S, MELE D, et al. MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma[J]. Oncoimmunology, 2022, 11( 1): 2035919. DOI: 10.1080/2162402X.2022.2035919.
    [23]
    VITA F, OLAIZOLA I, AMATO F, et al. Heterogeneity of cholangiocarcinoma immune biology[J]. Cells, 2023, 12( 6): 846. DOI: 10.3390/cells12060846.
    [24]
    DIGGS LP, RUF B, MA C, et al. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma[J]. J Hepatol, 2021, 74( 5): 1145- 1154. DOI: 10.1016/j.jhep.2020.11.037.
    [25]
    CAZZETTA V, FRANZESE S, CARENZA C, et al. Natural killer-dendritic cell interactions in liver cancer: Implications for immunotherapy[J]. Cancers(Basel), 2021, 13( 9): 2184. DOI: 10.3390/cancers13092184.
    [26]
    SUNG E, KO M, WON JY, et al. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation[J]. Mol Ther, 2022, 30( 8): 2800- 2816. DOI: 10.1016/j.ymthe.2022.05.003.
    [27]
    WANG WM, GAO Y, XU JJ, et al. A NRF2 regulated and the immunosuppressive microenvironment reversed nanoplatform for cholangiocarcinoma photodynamic-gas therapy[J]. Adv Sci(Weinh), 2024, 11( 14): e2307143. DOI: 10.1002/advs.202307143.
    [28]
    XUE RD, ZHANG QM, CAO Q, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity[J]. Nature, 2022, 612( 7938): 141- 147. DOI: 10.1038/s41586-022-05400-x.
    [29]
    ZHOU ZJ, WANG PC, SUN RQ, et al. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3[J]. J Immunother Cancer, 2021, 9( 3): e001946. DOI: 10.1136/jitc-2020-001946.
    [30]
    WATANABE A, HARIMOTO N, ARAKI K, et al. Absolute neutrophil count predicts postoperative prognosis in mass-forming intrahepatic cholangiocarcinoma[J]. Anticancer Res, 2019, 39( 2): 941- 947. DOI: 10.21873/anticanres.13197.
    [31]
    ZHOU MH, WANG CQ, LU SN, et al. Tumor-associated macrophages in cholangiocarcinoma: Complex interplay and potential therapeutic target[J]. EBioMedicine, 2021, 67: 103375. DOI: 10.1016/j.ebiom.2021.103375.
    [32]
    ZENG JH, LIU ZK, SUN SW, et al. Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells[J]. Oncol Lett, 2018, 15( 6): 8681- 8686. DOI: 10.3892/ol.2018.8372.
    [33]
    SUN DL, LUO TC, DONG PP, et al. M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma[J]. J Cell Biochem, 2020, 121( 4): 2828- 2838. DOI: 10.1002/jcb.29514.
    [34]
    CHENG K, CAI N, ZHU JH, et al. Tumor-associated macrophages in liver cancer: From mechanisms to therapy[J]. Cancer Commun(Lond), 2022, 42( 11): 1112- 1140. DOI: 10.1002/cac2.12345.
    [35]
    RAGGI C, CORRENTI M, SICA A, et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages[J]. J Hepatol, 2017, 66( 1): 102- 115. DOI: 10.1016/j.jhep.2016.08.012.
    [36]
    QUARANTA V, BALLARÒ C, GIANNELLI G. Macrophages orchestrate the liver tumor microenvironment[J]. Cancers(Basel), 2024, 16( 9): 1772. DOI: 10.3390/cancers16091772.
    [37]
    LUO CB, XIN HY, ZHOU ZJ, et al. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression[J]. Hepatology, 2022, 76( 4): 982- 999. DOI: 10.1002/hep.32387.
    [38]
    TOMLINSON JL, VALLE JW, ILYAS SI. Immunobiology of cholangiocarcinoma[J]. J Hepatol, 2023, 79( 3): 867- 875. DOI: 10.1016/j.jhep.2023.05.010.
    [39]
    LIN YL, CAI Q, CHEN Y, et al. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase[J]. Hepatology, 2022, 75( 1): 28- 42. DOI: 10.1002/hep.32099.
    [40]
    AFFO S, YU LX, SCHWABE RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer[J]. Annu Rev Pathol, 2017, 12: 153- 186. DOI: 10.1146/annurev-pathol-052016-100322.
    [41]
    ZHENG Y, ZHOU C, YU XX, et al. Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-Catenin[J]. Cell Death Dis, 2018, 9( 2): 179. DOI: 10.1038/s41419-017-0226-x.
    [42]
    GRACIA-SANCHO J, CAPARRÓS E, FERNÁNDEZ-IGLESIAS A, et al. Role of liver sinusoidal endothelial cells in liver diseases[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 6): 411- 431. DOI: 10.1038/s41575-020-00411-3.
    [43]
    COGLIATI B, YASHASWINI CN, WANG S, et al. Friend or foe? The elusive role of hepatic stellate cells in liver cancer[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 10): 647- 661. DOI: 10.1038/s41575-023-00821-z.
    [44]
    YUAN H, LIN ZL, LIU YJ, et al. Intrahepatic cholangiocarcinoma induced M2-polarized tumor-associated macrophages facilitate tumor growth and invasiveness[J]. Cancer Cell Int, 2020, 20( 1): 586. DOI: 10.1186/s12935-020-01687-w.
    [45]
    ZHU CB, MA JQ, ZHU K, et al. Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma[J]. JHEP Rep, 2023, 5( 8): 100762. DOI: 10.1016/j.jhepr.2023.100762.
    [46]
    LIN YP, PENG LH, DONG LQ, et al. Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma[J]. Cancer Discov, 2022, 12( 10): 2350- 2371. DOI: 10.1158/2159-8290.CD-21-1640.
    [47]
    HONG JH, YONG CH, HENG H, et al. Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies[J]. Gut, 2024, 73( 6): 966- 984. DOI: 10.1136/gutjnl-2023-330483.
    [48]
    CHEN JL, TANG Y, QIN DL, et al. ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway[J]. J Transl Med, 2023, 21( 1): 923. DOI: 10.1186/s12967-023-04804-1.
    [49]
    XU LX, ZHANG Y, LIN ZL, et al. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma[J]. J Hepatol, 2024, 81( 2): 265- 277. DOI: 10.1016/j.jhep.2024.03.016.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (123) PDF downloads(17) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return